Additionally, we have recently demonstrated that long noncoding RNA RMRP is an inhibitor of p53 in response to PARPi treatment, while targeting RMRP significantly bolsters p53 activation and enhances tumor sensitivity to PARPi (29, 30). Here, TP53 is linked to neoplasm.